Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of pharmaceutical composition for treating lung cancer and its preparation method

A composition and drug technology, applied in the field of medicine, to achieve the effects of enhancing curative effect, reducing side effects, and improving drug resistance

Active Publication Date: 2021-03-19
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there is no relevant report on the combination of neogambogic acid and crocin to treat lung cancer at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition for treating lung cancer and its preparation method
  • A kind of pharmaceutical composition for treating lung cancer and its preparation method
  • A kind of pharmaceutical composition for treating lung cancer and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1. Neogambogic acid combined with crocin inhibits the proliferation of A549 cell lines

[0022] 1. Experimental materials

[0023] (1) Experimental cells:

[0024] Human lung cancer cell line (A549) was purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences.

[0025] (2) Pharmaceutical reagents:

[0026] New gambogic acid was purchased from Shanghai Yansheng Industrial Co., Ltd.;

[0027] Crocin was purchased from Sigma, USA.

[0028] 2. Experimental method

[0029] (1) Culture and treatment of human lung cancer cells (A549)

[0030] Human lung cancer cells (A549) were cultured in DMEM medium containing 10% fetal bovine serum and 1% double antibody (100U / ml penicillin, 100mg / L streptomycin), 37°C, 5% CO 2 Subculture in an incubator. The cells were subcultured twice a week, and the adherent cells were digested with 0.25% trypsin. The cells used in the experiment were all in the logarithmic growth phase.

[0031] (2) MTT method to d...

Embodiment 2

[0041] Example 2. Effect of neogambogic acid combined with crocin on inhibiting the growth of A549 cell transplanted tumor in nude mice

[0042] 1. Inoculation of A549 cell transplanted tumors in nude mice: BALB / c nude mice, 5-6 weeks old, male, weighing about 20 g, were bred. Subcutaneous inoculation and transplantation of cultured cells was adopted. Take A549 cells in the logarithmic growth phase, rinse the culture bottle twice with PBS, add 0.25% trypsin to digest, centrifuge and discard the supernatant, add 10ml of DMEM culture solution without fetal bovine serum, pipette to mix, discard the supernatant, repeat 1 time, then add serum-free DMEM medium, resuspend the cells, and adjust the cells to about 3×10 7 200 μl per mouse was inoculated subcutaneously under the armpit of the right forelimb of nude mice.

[0043] 2. Inhibitory effect of drugs on lung cancer xenografts in nude mice: the tumor grew 2 weeks after inoculation, and the tumor grew to 100-150mm 3 After that,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating lung cancer and a preparation method thereof. The pharmaceutical composition of the present invention contains neogambogic acid and crocin as active ingredients. When the neogambogic acid and the crocin are combined for use according to a weight ratio of 1:(0.5-2), a synergistic effect on treating non-small cell lung cancer is achieved, and growth of lung cancer cells and growth of tumors on the body surface of a tumor-bearing mouse can be remarkably inhibited. The combined use of the neogambogic acid and the crocin can enhance the curative effect and reduce the single drug dosage of the neogambogic acid and the crocin, and has the effects of improving drug resistance and reducing side effects. The pharmaceutical composition disclosed by the invention provides a scientific basis for developing new anti-lung cancer drugs, and has a good clinical application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a pharmaceutical composition for treating lung cancer and a preparation method thereof. Background technique [0002] Most lung cancers originate in the bronchial mucosal epithelium, and some also occur in the alveolar epithelium or bronchial glandular epithelium, so it is also called primary bronchial carcinoma. Lung cancer is one of the most common malignant tumors in the world, and the incidence of lung cancer worldwide is still increasing at a rate of 0.5% per year, and its incidence is on the rise. Only 20%-30% of lung cancer patients can be diagnosed early diagnosis. Smoking is the main cause of lung cancer. Lung cancer is divided into squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large cell carcinoma, and small cell carcinoma according to histopathology, and can also be divided into small cell lung cancer and non-small cell lung cancer. Among them, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61K31/7024A61P35/00
CPCA61K31/352A61K31/7024A61P35/00A61K2300/00
Inventor 客蕊刘志平王卓溪
Owner HEILONGJIANG UNIV OF CHINESE MEDICINE